New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design
Some experts say the talc study’s data limitations weaken its impact in the field.
Gynecologic, Ovarian, and Cervical Cancer
GYNECOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response. -
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection. -
Dual-Targeted CAR-T Therapies in Solid Tumors: Q&A With Dr Wayne Marasco
Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors. -
Research Shows How Talc Powder May Change Ovarian Cancer Cells
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
GYNECOLOGIC CANCER NEWS
Bevacizumab Adoption Tied to Use by Peers
Fertility-Sparing Surgery Achieves Good Oncologic, Obstetric Outcomes in Younger Women With Early-Stage Nonepithelial Ovarian Cancer
PALB2 Linked to Increased Risk for Breast, Ovarian, and Pancreatic Cancer
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer
Testing for Genetic Variants Informed the Use of Cancer Risk Assessments
Want to read more?
Please login or register first to view this content.
